摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-吡啶醛肟 | 696-53-7

中文名称
4-吡啶醛肟
中文别名
——
英文名称
anti-Isonicotinaldehyd-oxim
英文别名
pyridin-4-aldoxime;4-Pyridinecarboxaldehyde, oxime;(NZ)-N-(pyridin-4-ylmethylidene)hydroxylamine
4-吡啶醛肟化学式
CAS
696-53-7
化学式
C6H6N2O
mdl
——
分子量
122.126
InChiKey
OFYLBLSSPQTTHT-YVMONPNESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    169-171 °C
  • 沸点:
    233.1±13.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    45.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:242052e0d30f3d8ac6a4e250f8b3a4f8
查看

反应信息

  • 作为反应物:
    描述:
    4-吡啶醛肟sodium methylate乙腈 作用下, 以 甲醇乙醚 为溶剂, 反应 2.0h, 生成 O-(O,O-diethylphosphoryl)-1-methyl-4-pyridinium carboxaldehyde oxime methylsulfate
    参考文献:
    名称:
    Characterization of O,O-diethylphosphoryl oximes as inhibitors of cholinesterases and substrates of phosphotriesterases
    摘要:
    Reactivators of organophosphate (OP)-inhibited cholinesterases (ChEs) are believed to give rise to phosphorylated oximes (POX) that reinhibit the enzyme. Diethylphosphoryl oximes (DEP-OX) that were generated In situ were demonstrated in the past to be unstable, yet were more potent inhibitors of acetylcholinesterase (AChE) than the parent OPs. In view of the inconsistencies among reported results, and the potential toxicity of POXs, it seemed important to characterize authentic DEP-OXs, and to evaluate their interference with reactivation of diethylphosphoryl-ChE (DEP-ChE) conjugates. To this end, the diethylphosphoric acid esters of 1-methyl-2-pyridinium carboxaldehyde oxime (DEP-2PAM) and 1-methyl-4 pyridinium carboxaldehyde oxime (DEP-4PAM) were synthesized and chemically defined. The half-lives of DEP-2PAM and DEP-4PAM in 10 mM Tris buffer, pH 7.8, at 29 degrees were found to be 10 and 980 sec, respectively. The two DEP-OXs inhibited ChEs with the following ranking order: for DEP-2PAM, human butyrylcholinesterase (HuBChE, k(i) = 2.03 x 10(9) M-1 min(-1)) > mouse AChE (MoAChE) congruent to fetal bovine serum AChE (FBS-AChE) congruent to equine BChE (EqBChE); for DEP-4PAM, WuBChE (k(i) = 0.71 x 10(9) M-1 min(-1)) > EqBChE > MoAChE > FBS-AChE. A dialkylarylphosphate hydrolase (phosphotriesterase; PTE) from Pseudomonas sp. catalyzed the hydrolysis of DEP-4PAM with k(cat)/K-m = 3.56 x 10(7) M-1 min(-1) and K-m = 0.78 mM. Reactivation of DEP-ChEs was enhanced by PTE when di-PAM-based oximes were used as reactivators, whereas reactivation with 2-PAM-based oximes was not affected by PTE. This observation is attributed primarily to the short half-life of DEP-OXs derived from the latter oximes. Relatively low doses of PTE can detoxify large quantities of DEP-OXs rapidly, and thereby augment the efficacy of antidotes that contain the oxime function in position 4 of the pyridine ring. (C) 1999 Elsevier Science Inc.
    DOI:
    10.1016/s0006-2952(99)00117-3
  • 作为产物:
    描述:
    4-吡啶甲醛盐酸羟胺sodium carbonate 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以72.222%的产率得到
    参考文献:
    名称:
    TGR5激动剂3,4,5-三取代的4,5-二氢-1,2,4-恶二唑的设计,合成与结构-活性关系
    摘要:
    鉴于其在能量和葡萄糖稳态中的介导作用,G蛋白偶联胆汁酸受体1(TGR5)被认为是治疗2型糖尿病和其他代谢性疾病的潜在靶标。通过对已发表的TGR5激动剂的各种结构进行全面分析,建立了一个假设的基于配体的药效团模型,并基于新型3,4,5-三取代的4,5-二氢-1,2来开发了一类新型的强效TGR5激动剂。 ,4-恶二唑核是通过合理设计发现的。本文报道了三种不同的合成方法来构建4,5-二氢-1,2,4-恶二唑和广泛的结构-活性关系研究。化合物(R)-54 n,其结构是通过单晶X-射线衍射和量子化学固态TDDFT-ECD计算确定,显示出最好的效力,用EC 50为1.4的n值中号朝向hTGR5。它在体外的有利特性值得进一步研究。
    DOI:
    10.1002/cmdc.201300144
点击查看最新优质反应信息

文献信息

  • Substituted Indole Compounds
    申请人:Schunk Stefan
    公开号:US20100222324A1
    公开(公告)日:2010-09-02
    Substituted indole compounds corresponding to the formula I: In which R 8 , R 9a , R 9b , R 10 , R 11 , R 200 , R 210 , A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).
    将与下式I对应的吲哚化合物替代: 其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义,其制备方法,含有这种化合物的药物组合物以及用于治疗或抑制至少部分由Bradykinin 1受体(B1R)介导的疼痛和其他病症的替代吲哚化合物的用途。
  • MULTIFUNCTIONAL SMALL MOLECULES
    申请人:The Regents of the University of Michigan
    公开号:US20150216993A1
    公开(公告)日:2015-08-06
    The present invention relates to novel therapeutic dendrimer conjugates configured for the treatment and/or prevention of organophosphate poisoning. In particular, the present invention is directed to dendrimers complexed with organophosphate poisoning antidotes (e.g., pralidoxime (2-PAM) (4-PAM), obidoxime, trimedoxime, asoxime (HI-6), hydroxamate, and related analogs, salts and derivatives thereof), compositions comprising such dendrimer conjugates, related methods of synthesizing such dendrimer conjugates, as well as systems and methods utilizing such dendrimer conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in the treatment and/or prevention of organophosphate poisoning)).
    本发明涉及用于治疗和/或预防有机磷酸盐中毒的新型治疗性树状大分子偶联物。特别是,本发明涉及与有机磷酸盐中毒解毒剂(例如,普瑞洛霉素(2-PAM)(4-PAM),奥比多西姆,三甲多西姆,阿索西姆(HI-6),羟基酰胺以及相关的类似物,盐和衍生物)复合的树状大分子,包含这样的树状大分子偶联物的组合物,合成这样的树状大分子偶联物的方法,以及利用这样的树状大分子偶联物(例如,在诊断和/或治疗环境中(例如,用于治疗剂,成像和/或靶向剂(例如,在治疗和/或预防有机磷酸盐中毒)的递送))的系统和方法。
  • [EN] SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES<br/>[FR] BENZIMIDAZOLES, BENZOTHIAZOLES ET BENZOXAZOLES SUBSTITUÉS
    申请人:GRUENENTHAL GMBH
    公开号:WO2010142402A1
    公开(公告)日:2010-12-16
    The present invention relates to substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.
    本发明涉及取代苯并咪唑苯并噻唑和苯并噁唑,其制备方法,含有这些化合物的药物以及利用这些化合物制备药物的用途。
  • ISOXAZOLE-PYRIDINE DERIVATIVES
    申请人:Buettelmann Bernd
    公开号:US20090143371A1
    公开(公告)日:2009-06-04
    The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.
    本发明涉及式I的异恶唑-吡啶衍生物 其中X,R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性,并可用于治疗认知障碍,如阿尔茨海默病。
  • [EN] HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE<br/>[FR] SULFAMIDES SPIROCYCLIQUES SUBSTITUES PAR HETEROARYLE UTILISES COMME INHIBITEURS DE LA GAMMA-SECRETASE
    申请人:MERCK SHARP & DOHME
    公开号:WO2003093252A1
    公开(公告)日:2003-11-13
    Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.
    公式I的化合物已被披露:其中X是一个5-成员杂环芳基环,R如本文所定义。这些化合物是γ-分泌酶对APP加工的抑制剂,因此在治疗或预防阿尔茨海默病中是有用的。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-